New scan spots hidden heart disease in gene carriers before symptoms start

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

A. Pathogenic TTR Allele Carriers without HF Inclusion: * men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician) * have already completed the protocol for NCT05489549 at UT Southwestern only Exclusion: * a self-reported history or clinical history of HF * other known causes of cardiomyopathy * history of light-chain cardiac amyloidosis * prior type 1 myocardial infarction * cardiac transplantation * liver transplantation * body weight or habitus that exceeds the site-specific PET/CT parameters * estimated glomerular filtration rate ≤30 mL/min/1.73 m2 * inability to safely undergo PET/CT * participating in a clinical trial for ATTR treatments or taking a fibril deleting agent * pregnancy or breastfeeding * patients taking heparin or heparin derivatives for anticoagulation * allergy to potassium iodide * known uncorrected thyroid disorder B. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment): Inclusion: * men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician) * hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein * TTR gene sequencing confirming the TTR variant * have already completed the protocol for NCT05489549 at UT Southwestern only Exclusion: * other known causes of cardiomyopathy * history of light-chain cardiac amyloidosis * cardiac transplantation * liver transplantation * history of type I myocardial infarction * body weight or habitus that exceeds the site-specific PET/CT parameters * estimated glomerular filtration rate ≤30 mL/min/1.73 m2 * inability to safely undergo PET/CT * participating in a clinical trial for ATTR treatments or taking a fibril deleting agent * patients taking heparin or heparin derivatives for anticoagulation * pregnancy or breastfeeding * allergy to potassium iodide * known uncorrected thyroid disorder C. Non-carrier race-matched controls: Inclusion: * men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician * have previously enrolled in the Dallas Heart Study Exclusion: * a self-reported history or clinical history of HF * other known causes of cardiomyopathy * history of light-chain cardiac amyloidosis * prior type 1 myocardial infarction * cardiac transplantation * liver transplantation * body weight or habitus that exceeds the site-specific PET/CT parameters * estimated glomerular filtration rate ≤30 mL/min/1.73 m2 * inability to safely undergo PET/CT * participating in a clinical trial for ATTR treatments or taking a fibril deleting agent * patients taking heparin or heparin derivatives for anticoagulation * pregnancy or breastfeeding * allergy to potassium iodide * known uncorrected thyroid disorder